Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabrizio Giordanetto

Showing results (1-10 of 70) with videos related to

Pageof 7
Sort By:
Drug Discovery Today|December 24, 2014
Small molecule inhibitors of ebola virus infectionEdwige Picazo, Fabrizio Giordanetto
Journal of Medicinal Chemistry|September 19, 2013
Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties?Fabrizio Giordanetto, Jan Kihlberg
Expert Opinion on Therapeutic Patents|November 10, 2012
Direct AMP-activated protein kinase activators: a review of evidence from the patent literatureFabrizio Giordanetto, David Karis
Protein Engineering|November 29, 2002
Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7Fabrizio Giordanetto, Romano T Kroemer
Protein Engineering|April 5, 2003
A three-dimensional model of Suppressor Of Cytokine Signalling 1 (SOCS-1)Fabrizio Giordanetto, Romano T Kroemer
Nature Genetics|March 28, 2008
Re-examining the role of cytochrome c in cell deathEric Solary, Fabrizio Giordanetto, Guido Kroemer
Drug Discovery Today|September 1, 2014
Stabilization of protein-protein interactions by small moleculesFabrizio Giordanetto, Anja Schäfer, Christian Ottmann
Molecular Cell|October 27, 2009
Targeting HSP70 for cancer therapyLorenzo Galluzzi, Fabrizio Giordanetto, Guido Kroemer
Drug Discovery Today|June 11, 2011
Follow-on drugs: how far should chemists look?Fabrizio Giordanetto, Jonas Boström, Christian Tyrchan
Bioorganic & Medicinal Chemistry Letters|December 21, 2010
Discovery of novel class 1 phosphatidylinositide 3-kinases (PI3K) fragment inhibitors through structure-based virtual screeningFabrizio Giordanetto, Bengt Kull, Anita Dellsén
Pageof 7

Showing results (1-10 of 70) with videos related to

Sort By:
Pageof 7
Drug Discovery Today|December 24, 2014
Small molecule inhibitors of ebola virus infectionEdwige Picazo, Fabrizio Giordanetto
Journal of Medicinal Chemistry|September 19, 2013
Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties?Fabrizio Giordanetto, Jan Kihlberg
Expert Opinion on Therapeutic Patents|November 10, 2012
Direct AMP-activated protein kinase activators: a review of evidence from the patent literatureFabrizio Giordanetto, David Karis
Protein Engineering|November 29, 2002
Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7Fabrizio Giordanetto, Romano T Kroemer
Protein Engineering|April 5, 2003
A three-dimensional model of Suppressor Of Cytokine Signalling 1 (SOCS-1)Fabrizio Giordanetto, Romano T Kroemer
Nature Genetics|March 28, 2008
Re-examining the role of cytochrome c in cell deathEric Solary, Fabrizio Giordanetto, Guido Kroemer
Drug Discovery Today|September 1, 2014
Stabilization of protein-protein interactions by small moleculesFabrizio Giordanetto, Anja Schäfer, Christian Ottmann
Molecular Cell|October 27, 2009
Targeting HSP70 for cancer therapyLorenzo Galluzzi, Fabrizio Giordanetto, Guido Kroemer
Drug Discovery Today|June 11, 2011
Follow-on drugs: how far should chemists look?Fabrizio Giordanetto, Jonas Boström, Christian Tyrchan
Bioorganic & Medicinal Chemistry Letters|December 21, 2010
Discovery of novel class 1 phosphatidylinositide 3-kinases (PI3K) fragment inhibitors through structure-based virtual screeningFabrizio Giordanetto, Bengt Kull, Anita Dellsén
Pageof 7